UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934

 

For the Month of June 2014

 

001-36345
(Commission File Number)

 

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

 

8 Shaul Hamelech Blvd.

Amot Hamishpat Bldg.

Tel Aviv 6473307, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.

 

Form 20-F þ Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ____

  

 

On June 4, 2014, Galmed Pharmaceuticals Ltd. (the “Company”) issued a press release announcing the recent publication of independent pre-clinical data supporting the importance of ABCA1-induced reverse cholesterol transport on the pathogenesis of Non-Alcoholic Steato-Hepatitis. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

 

Exhibit Index

 

Exhibit No.		Description
99.1		Press Release, dated June 4, 2014

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Galmed Pharmaceuticals Ltd.
Date:  June 4, 2014	By:	/s/ Allen Baharaff
	Allen Baharaff
	Chief Executive Officer